A comprehensive view of Oral Medicines/Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion
Published: June 22, 2022 by Investor's Business Daily
Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month
Published: June 22, 2022 by Business Wire
Pfizer partners with MorphoSys, Incyte to evaluate combined therapy to treat diffuse large B-cell lymphoma, a type of blood cancer; drugs include Pfizer’s experimental TTI-622, Morphosys and Incyte’s Monjuvi tafasitamab-cxix, Revlimid lenalidomide
Published: June 15, 2022 by SeeNews Pharmaceuticals
Pfizer completes acquisition of biopharmaceutical firm ReViral for US$525M; deal includes ReViral’s sisunatovir oral treatment for respiratory pathogen RSV, which affects 64 million people worldwide each year, causing 160,000 deaths
Published: June 14, 2022 by Business Wire
FDA approves Eli Lilly’s Olumiant oral treatment for alopecia areata, an autoimmune disorder that causes sudden hair loss; once-daily pill is first treatment of its kind and is available by prescription only
Published: June 14, 2022 by STAT News

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count